Anti-JAK3 抗体 [EP909Y] (ab45141)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EP909Y] to JAK3
- Suitable for: Flow Cyt (Intra), WB, IP, IHC-P, ICC/IF
- Reacts with: Human
Related conjugates and formulations
製品の概要
-
製品名
Anti-JAK3 antibody [EP909Y]
JAK3 一次抗体 製品一覧 -
製品の詳細
Rabbit monoclonal [EP909Y] to JAK3 -
由来種
Rabbit -
アプリケーション
適用あり: Flow Cyt (Intra), WB, IP, IHC-P, ICC/IFmore details -
種交差性
交差種: Human -
免疫原
Synthetic peptide within Human JAK3 aa 1100 to the C-terminus (C terminal). The exact sequence is proprietary.
Database link: P52333 -
ポジティブ・コントロール
- Flow Cyt (intra): Jurkat cells. WB: TF-1 cell lysate, HEL, KARPAS-299, HaCaT. IHC-P: Human NK cell lymphoma, Human large B cell lymphoma ICC/IF: KARPAS-299IP: TF-1 whole cell lysate
-
特記事項
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. -
バッファー
pH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 50% Tissue culture supernatant -
Concentration information loading...
-
精製度
Tissue culture supernatant -
ポリ/モノ
モノクローナル -
クローン名
EP909Y -
アイソタイプ
IgG -
研究分野
関連製品
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab45141の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
Flow Cyt (Intra) |
1/100.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
|
WB |
1/2000. Predicted molecular weight: 125 kDa.
|
|
IP |
1/60.
|
|
IHC-P |
Use at an assay dependent concentration. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
|
|
ICC/IF | (1) |
Use at an assay dependent concentration.
|
特記事項 |
---|
Flow Cyt (Intra)
1/100. ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
WB
1/2000. Predicted molecular weight: 125 kDa. |
IP
1/60. |
IHC-P
Use at an assay dependent concentration. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
ICC/IF
Use at an assay dependent concentration. |
ターゲット情報
-
機能
Tyrosine kinase of the non-receptor type, involved in the interleukin-2 and interleukin-4 signaling pathway. Phosphorylates STAT6, IRS1, IRS2 and PI3K. -
組織特異性
In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins. -
関連疾患
Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-) SCID) [MIM:600802]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. -
配列類似性
Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.
Contains 1 FERM domain.
Contains 1 protein kinase domain.
Contains 1 SH2 domain. -
ドメイン
Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of slight differences suggest a different role for domain 1. -
翻訳後修飾
Tyrosine phosphorylated in response to IL-2 and IL-4. -
細胞内局在
Endomembrane system. Wholly intracellular, possibly membrane associated. - Information by UniProt
-
参照データベース
- Entrez Gene: 3718 Human
- Omim: 600173 Human
- SwissProt: P52333 Human
- Unigene: 515247 Human
-
別名
- EC 2.7.10.2 antibody
- JAK 3 antibody
- JAK L antibody
see all
画像
-
All lanes : Anti-JAK3 antibody [EP909Y] (ab45141) at 1/1000 dilution
Lane 1 : TF-1 (Human Erythroleukemia erythroblast) whole cell lysate
Lane 2 : HaCaT (Human skin keratinocyte) whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 125 kDa
Observed band size: 125 kDa
Exposure time: 3 minutesBlocking/Diluting buffer and concentration 5% NFDM/TBST
The expression profile observed in HaCaT is consistent with the literature (PMID: 11709700).
Negative control: HaCaT (PMID: 11709700) -
Immunocytochemistry/Immunofluorescence analysis of KARPAS-299 (human anaplastic large cell lymphoma) labelling JAK3 with ab45141 at a dilution of 1:100 dilution (12 µg/ml). Cells were fixed with 100% Methanol. Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) (1:1000 dilution (2 µg/ml)) was used as the secondary antibody. The cells were co-stained with Ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) 1:200 (2.5 µg/ml). Nuclei counterstained with DAPI (blue). Control: PBS instead of the primary antibody.
-
All lanes : Anti-JAK3 antibody [EP909Y] (ab45141) at 1.21 µg/ml
Lane 1 : KARPAS-299 (Human anaplastic large cell lymphoma ) whole cell lysate
Lane 2 : HEL (Human Erythroleukemia erythroblast ) whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 125 kDa
Observed band size: 125 kDa
Exposure time: 26 secondsBlocking and diluting buffer: 5% NFDM/TBST.
-
Lane 1 (input): TF-1 (Human Erythroleukemia erythroblast) whole cell lysate, 10µg
Lane 2 (+): TF-1 whole cell lysate
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab45141 in TF-1 whole cell lysate.
ab45141 at 1/60 immunoprecipitating JAK3 in TF-1 whole cell lysate. For western blotting, ab45141 was used as a primary antibody at 1/500 dilution (2.42 µg/ml). ab131366, VeriBlot for IP Detection Reagent was used for detection at 1/1000 dilution. Blocking and diluting buffer used was 5% NFDM/TBST. -
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-JAK3 antibody [EP909Y] (ab45141)
Immunohistochemistry (Formalin/PFA-fixed paraffin embedded sections) analysis of Human NK cell lymphoma tissue sections labeling JAK3 using purified ab45141. Samples were incubated the primary antibody at 1:2000 dilution (0.60 μg/ml). Hematoxylin was used as a counterstain. PBS instead of primary antibody was used for negative control. A ready to use ImmunoHistoProbe one step HRP Polymer at 1:0 dilution was used as the secondary antibody. Heatm mediated antigen retrieval was performed using ab93684 (Tris/EDTA buffer, pH 9.0).
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-JAK3 antibody [EP909Y] (ab45141)
Immunohistochemistry (Formalin/PFA-fixed paraffin embedded sections) analysis of Human large B cell lymphoma tissue sections labeling JAK3 using purified ab45141. Samples were incubated the primary antibody at 1:2000 dilution (0.60 μg/ml). Hematoxylin was used as a counterstain. PBS instead of primary anitbody was used for negative control. A ready to use ImmunoHistoProbe one step HRP Polymer at 1:0 dilution was used as the secondary antibody. Heatm mediated antigen retrieval was performed using ab93684 (Tris/EDTA buffer, pH 9.0).
-
Anti-JAK3 antibody [EP909Y] (ab45141) at 1/2000 dilution + TF-1 (Human bone marrow erythroleukemia cell line) cell lysate
Predicted band size: 125 kDa
Observed band size: 125 kDa -
Overlay histogram showing Jurkat (Human T cell leukemia cell line from peripheral blood) cells stained with ab45141 (red line). The cells were fixed with 80% methanol (5 minutes) and then permeabilized with 0.1% PBS-Tween for 20 minutes. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab45141, 1/100 dilution) for 30 minutes at 22°C. The secondary antibody used was DyLight® 488 goat anti-rabbit IgG (H+L) (ab96899) at 1/500 dilution for 30 minutes at 22°C. Isotype control antibody (black line) was rabbit IgG (1µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in Jurkat cells fixed with 4% paraformaldehyde (10 minutes)/permeabilized in 0.1% PBS-Tween used under the same conditions.
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (12)
ab45141 は 12 報の論文で使用されています。
- Chen Y et al. LncRNA-PVT1 was identified as a key regulator for TMZ resistance and STAT-related pathway in glioma. BMC Cancer 23:455 (2023). PubMed: 37202742
- Li C et al. Suppressive function of bone marrow-derived mesenchymal stem cell-derived exosomal microRNA-187 in prostate cancer. Cancer Biol Ther 23:1-14 (2022). PubMed: 36245088
- Long Q et al. Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma. J Adv Res 40:153-166 (2022). PubMed: 36100323
- Xu L et al. FABP4 activates the JAK2/STAT2 pathway via Rap1a in the homocysteine-induced macrophage inflammatory response in ApoE-/- mice atherosclerosis. Lab Invest 102:25-37 (2022). PubMed: 34725437
- Zhang J et al. CD105 expression is associated with invasive capacity in ovarian cancer and promotes invasiveness by inhibiting NDRG1 and regulating the epithelial-mesenchymal transition. Am J Transl Res 13:12461-12479 (2021). PubMed: 34956466